The $400,000 SBIR Phase I award will support development of Tiba’s tissue-targeted delivery platform and proprietary enhanced self-amplifying RNA payloads.
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
Tiba Biotech receives a Notice of Intent from NIAID to fund a Phase I SBIR to develop a novel RNA vaccine against a deadly tick bourn disease with the Cummings School for Veterinary Medicine
Tiba Biotech receives a Phase I SBIR grant from NIAID to develop a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
Tiba scientists are working with academic collaborators at the University of Pittsburg and Carnegie Mellon University to design a 3D printed micro-needle patch for intradermal mRNA vaccine delivery.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Tiba scientists are working with our academic collaborators at the University of Pittsburg and Carnegie Mellon University to design a new approach to mRNA vaccine delivery. The combined stability of our nanoparticles and the dosing efficiency of a micro-needle patch offer new opportunities for healthcare professionals in resource-limited settings.
Leveraging the University’s Center for Vaccine Research, an NIH Regional Biocontainment Laboratory, Tiba scientists are collaborating with researchers at the University of Pittsburg to advance a novel COVID-19 mRNA vaccine.
© 2024 Tiba Biotech LLC. All rights reserved
Keep connected with us
Terms and Conditions
